Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Usana Health Sciences (USNA) over the last 15 years, with Q3 2025 value amounting to $3.2 million.

  • Usana Health Sciences' Capital Expenditures rose 3330.55% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 1773.0%. This contributed to the annual value of $10.1 million for FY2024, which is 3050.23% down from last year.
  • Usana Health Sciences' Capital Expenditures amounted to $3.2 million in Q3 2025, which was up 3330.55% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Usana Health Sciences' Capital Expenditures registered a high of $7.3 million during Q4 2023, and its lowest value of -$847000.0 during Q1 2022.
  • Over the past 5 years, Usana Health Sciences' median Capital Expenditures value was $2.7 million (recorded in 2024), while the average stood at $2.7 million.
  • In the last 5 years, Usana Health Sciences' Capital Expenditures crashed by 7802.09% in 2021 and then surged by 48783.94% in 2022.
  • Over the past 5 years, Usana Health Sciences' Capital Expenditures (Quarter) stood at $1.6 million in 2021, then skyrocketed by 105.7% to $3.3 million in 2022, then soared by 122.95% to $7.3 million in 2023, then crashed by 75.4% to $1.8 million in 2024, then skyrocketed by 77.47% to $3.2 million in 2025.
  • Its Capital Expenditures stands at $3.2 million for Q3 2025, versus $5.0 million for Q2 2025 and $2.8 million for Q1 2025.